Last updated on May 2019

Efficacy and Safety Study of EG12014 Compared With Herceptin in Subjects With HER2 Positive Early Breast Cancer

Brief description of study

The purpose of this research study is to compare the efficacy and safety of EG12014 with Herceptin as neoadjuvant treatment for 12 weeks, followed by surgery and subsequent EG12014 or Herceptin adjuvant treatment for up to 12 months.

Clinical Study Identifier: NCT03433313

Find a site near you

Start Over

Medical Oncology Centre of Rosebank

Johannesburg, South Africa
  Connect »